The drug Gefitinib was approved by the FDA in 2015 to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R). The drug, Gefitinib comes in the form of tablets in 250 mg to administer orally. Gefitinib is a kinase inhibitor that reversibly inhibits the kinase activity of wild-type and specific activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor inhibiting further downstream signaling, and blocking EGFR-dependent proliferation. Like any other medicine, Gefitinib has common side effects such as rashes, diarrhoea, nausea, headache, vomiting, dehydration, skin reactions, cough, loss of appetite, sore throat, and fever.
Gefitinib price is economical, and one can find this medicine from any licensed generic medicine supplier. For further information regarding this drug, contact us on toll-free no. 18008891064.
0
